v3.20.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Revenue
Expenses:    
Research and development 16,835 18,733
General and administrative 10,022 10,374
Operating expenses 26,857 29,107
Other income (expense):    
Interest income 574 283
Foreign exchange gain/(loss) 6 (44)
Total other income 580 239
Net loss (26,277) (28,868)
Other comprehensive loss:    
Unrealized gain on securities available-for-sale 18
Total comprehensive loss $ (26,259) $ (28,868)
Basic and diluted loss per common share (in dollars per share) $ (0.52) $ (0.86)
Weighted average number of common shares outstanding used in the calculation of (in thousands) Basic and diluted loss per common share (in shares) 50,160 33,391

Source